Clinical trials: High Risk Cancer
Melanoma
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of sequential therapy of pembrolizumab followed by HD IL-2 in subjects with stage IV malignant…
- Trial name
- NCT03476174
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph Hauke
Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between…
- Conditions
- Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation, Patients Decision Aids
- Trial name
- NCT05500118
- Testing
- Patients Decision Aids
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Maternity & Child Healthcare Hospital
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004082
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Brain Tumor, Central Nervous System Tumor
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006024
- Testing
- lomustine, temozolomide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
High Grade Glioma
Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Improved outcomes for high-grade gliomas (HGG) require advances in our ability to monitor changes to tumour biology using non-surgical approaches.
- Trial name
- m-ctDNA (NCT05925218)
- Testing
- Radiotherapy as per standard of care
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04128748
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Early-stage Breast Cancer, Carbohydrate Engorgement
Breast Cancer Diet Intervention Study
The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue.
- Conditions
- Early-stage Breast Cancer, Carbohydrate Engorgement, Proliferation, Insulin Resistance
- Trial name
- BCDIS (NCT03886389)
- Testing
- PreOP
- Volunteers
- 80 people
- Sponsor
- Helse Stavanger HF
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Breast Carcinoma
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer.
- Trial name
- NCT07216274
- Testing
- QT Ultrasound Breast Scanner, Questionnaire Administration
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Colorectal Cancer, SGLT-2 Inhibitor
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
Colorectal cancer (CRC), ranking third in incidence among men and second in women globally with third-highest mortality in the US, remains a major health challenge despite multimodal therapies, particularly for advanced-stage…
- Trial name
- NCT07076823
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04476459
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Huiqiang Huang
Colorectal Cancer, Colorectal Carcinoma
Microsatellite Instability in Colorectal Cancers
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Microsatellite Instability High, Microsatellite Instability Low
- Trial name
- MSI-CRC (NCT05162248)
- Testing
- Microsatellite instability analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 231 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Breast Cancer
Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
This protocol will evaluate the feasibility and toxicity of dose-dense docetaxel followed by doxorubicin and cyclophosphamide with support given as adjuvant or neoadjuvant treatment of women with node positive and high risk…
- Trial name
- NCT00193115
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk…
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT00588991
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Cervical Cancer
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
Primary Objectives To investigate the relationship between dynamic MRI, brain tumor perfusion (DSC) and permeability (DCE), and dynamic 18F-FAZA PET uptake.
- Trial name
- NCT05047913
- Testing
- 18F-FTX
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.